Amgen will present eight Imlygic (talimogene laherparepvec) abstracts, including data from the Phase 3 trial and new data from its Phase 1b combination trial with Merck’s anti-PD-1 therapy, at the 12th International Congress of the Society for Melanoma Research (SMR), on November 18-21, to be held in San Francisco.
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen said that the analyses from Amgen’s Phase 3 monotherapy trial confirm the clinical significance of durable responses and the benefit Imlygic may bring to patients living with metastatic melanoma.
He said: “As we advance understanding in the emerging science of oncolytic viral therapy, we are also excited to share early data on the use of Imlygic in combination with another immunotherapy.”
The 2015 Society for Melanoma Research International Congress provides the opportunity for the innovative data related to clinical and basic melanoma research to be presented and reviewed, and to network with an international audience.